By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Biomedical Advanced Research and Development Authority (BARDA) 

330 C Street, SW
Room G640
Washington  D.C.  20201  U.S.A.
Phone: 202-260-1200 Fax: 202-205-4520


SEARCH JOBS


Industry
Government
Services






Company News
Novavax, Inc. (NVAX) Announces Biomedical Advanced Research and Development Authority (BARDA) Exercise Of Contract Option 9/23/2014 8:25:00 AM
Chimerix, Inc. (CMRX) And Biomedical Advanced Research and Development Authority (BARDA) Announce Continued Partnership In The Development Of Brincidofovir For Smallpox 9/2/2014 9:17:26 AM
Biomedical Advanced Research and Development Authority (BARDA) Extends Contract With Cytori Therapeutics, Inc. (CYTX) For Burn Treatment, Deal Is Worth Up To $20.4 Million 8/19/2014 8:58:20 AM
Cytori Therapeutics, Inc. (CYTX) Receives Notice Of Intent To Exercise First Contract Option From Biomedical Advanced Research and Development Authority (BARDA) 7/7/2014 10:16:54 AM
Biota Pharmaceuticals, Inc. Provides Update On Biomedical Advanced Research and Development Authority (BARDA) Contract For Laninamivir Octanoate 5/8/2014 1:02:51 PM
Novavax, Inc. (NVAX) Announces Extension Of Contract For Advanced Development Of Recombinant Influenza Products And Pandemic Preparedness With Department of Health and Human Services-Biomedical Advanced Research and Development Authority (BARDA) 2/28/2014 9:48:42 AM
The Medicines Company (MDCO) Wins Biomedical Advanced Research and Development Authority (BARDA) Antibiotic Contract Worth Up To $90 Million 2/5/2014 6:28:30 AM
Theraclone Sciences, Inc. Gets Bad News From Biomedical Advanced Research and Development Authority (BARDA) Regarding Pandemic Flu Drug 11/27/2013 7:44:03 AM
Argentum Medical LLC Awarded Biomedical Advanced Research and Development Authority (BARDA) Contract Valued Up to $16.5 Million 10/22/2013 6:28:21 AM
Biomedical Advanced Research and Development Authority (BARDA) Exercises Option With Pfenex Inc. to Extend Contract and Increase Funding for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine 10/1/2013 9:32:12 AM
12345678
//-->